{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T13:40:09Z","timestamp":1745588409271,"version":"3.40.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-024-00554-7","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T13:52:44Z","timestamp":1735912364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the consumption pattern and efficacy of Linezolid in COVID-19 hospitalized patients in a hospital in Tehran-Iran"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1968-8614","authenticated-orcid":false,"given":"Alireza","family":"Tavasoli Rostami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2046-6321","authenticated-orcid":false,"given":"Morteza","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3455-7013","authenticated-orcid":false,"given":"Mohsen","family":"Saberi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-4744","authenticated-orcid":false,"given":"Mehdi","family":"Raei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3405-9858","authenticated-orcid":false,"given":"Mostafa","family":"Soodmand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-5257","authenticated-orcid":false,"given":"Khadijeh","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2415-1164","authenticated-orcid":false,"given":"Hossein","family":"Mardani Nafchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0252-4230","authenticated-orcid":false,"given":"Mahdi","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"issue":"3","key":"554_CR1","first-page":"e7386","volume":"12","author":"DN Valencia","year":"2020","unstructured":"Valencia DN. Brief review on COVID-19: the 2020 pandemic caused by SARS-CoV-2. Cureus. 2020;12(3):e7386.","journal-title":"Cureus."},{"issue":"7","key":"554_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/pathogens9070519","volume":"9","author":"YS Malik","year":"2020","unstructured":"Malik YS, Kumar N, Sircar S, et al. Coronavirus disease pandemic (COVID-19): challenges and a global perspective. Pathogens. 2020;9(7):519.","journal-title":"Pathogens"},{"issue":"03","key":"554_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3855\/jidc.12671","volume":"14","author":"C Contini","year":"2020","unstructured":"Contini C, Di Nuzzo M, Barp N, et al. The novel zoonotic COVID-19 pandemic: An expected global health concern. J Infect Dev Countries. 2020;14(03):254\u201364.","journal-title":"J Infect Dev Countries"},{"issue":"4","key":"554_CR4","first-page":"571","volume":"36","author":"Z-W Ye","year":"2020","unstructured":"Ye Z-W, Jin D-Y. Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future. Sheng wu gong cheng xue bao= Chin J Biotechnol. 2020;36(4):571\u201392.","journal-title":"Sheng wu gong cheng xue bao= Chin J Biotechnol"},{"key":"554_CR5","unstructured":"Cascella M, Rajnik M, Aleem A, et al. Features, evaluation, and treatment of Coronavirus (COVID-19). 2023 Aug 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024."},{"issue":"1","key":"554_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5582\/bst.2020.01020","volume":"14","author":"H Lu","year":"2020","unstructured":"Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69\u201371.","journal-title":"Biosci Trends"},{"key":"554_CR7","doi-asserted-by":"crossref","unstructured":"Reardon S. Antibiotic treatment for COVID-19 complications could fuel resistant bacteria. Available from: https:\/\/www.science.org\/content\/article\/antibiotic-treatment-covid-19-complications-could-fuel-resistant-bacteria. Accessed 16 Apr 2020.","DOI":"10.1126\/science.abc2995"},{"issue":"10229","key":"554_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054\u201362.","journal-title":"Lancet"},{"issue":"1","key":"554_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s41182-021-00344-w","volume":"49","author":"YA Adebisi","year":"2021","unstructured":"Adebisi YA, Jimoh ND, Ogunkola IO, et al. The use of antibiotics in COVID-19 management: a rapid review of national treatment guidelines in 10 African countries. Trop Med Health. 2021;49(1):51.","journal-title":"Trop Med Health"},{"issue":"8 Suppl 6","key":"554_CR10","first-page":"23","volume":"14","author":"DH Batts","year":"2000","unstructured":"Batts DH. Linezolid\u2013a new option for treating gram-positive infections. Oncology (Williston Park). 2000;14(8 Suppl 6):23\u20139.","journal-title":"Oncology (Williston Park)"},{"issue":"5","key":"554_CR11","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S1471-4892(01)00082-0","volume":"1","author":"GE Zurenko","year":"2001","unstructured":"Zurenko GE, Gibson JK, Shinabarger DL, et al. Oxazolidinones: a new class of antibacterials. Curr Opin Pharmacol. 2001;1(5):470\u20136.","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"554_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1021\/jm9509556","volume":"39","author":"SJ Brickner","year":"1996","unstructured":"Brickner SJ, Hutchinson DK, Barbachyn MR, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem. 1996;39(3):673\u20139.","journal-title":"J Med Chem"},{"issue":"10","key":"554_CR13","doi-asserted-by":"publisher","first-page":"864","DOI":"10.7326\/0003-4819-139-10-200311180-00018","volume":"139","author":"RC Moellering Jr","year":"2003","unstructured":"Moellering RC Jr. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;139(10):864.","journal-title":"Ann Intern Med"},{"issue":"3","key":"554_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3855\/jidc.19205","volume":"18","author":"RA Eid","year":"2024","unstructured":"Eid RA, Elgendy MO, Sayed AM, et al. Efficacy of Linezolid in the management of pneumonic COVID-19 patients. Bioinformatics-based clinical study. J Infect Dev Countries. 2024;18(3):326\u201331.","journal-title":"J Infect Dev Countries"},{"key":"554_CR15","first-page":"198","volume":"71","author":"VD Moghadam","year":"2021","unstructured":"Moghadam VD, Momenimovahed Z, Ghorbani M, et al. Linezolid a potential treatment for COVID-19 coinfections. Braz J Anesthesiol. 2021;71:198\u2013198.","journal-title":"Braz J Anesthesiol"},{"key":"554_CR16","unstructured":"Zhang J, Ma X, Yu F, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. biorxiv. 2020."},{"issue":"7","key":"554_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2471\/BLT.20.268573","volume":"98","author":"H Getahun","year":"2020","unstructured":"Getahun H, Smith I, Trivedi K, et al. Tackling antimicrobial resistance in the COVID-19 pandemic. Bull World Health Organ. 2020;98(7):442.","journal-title":"Bull World Health Organ"},{"issue":"3","key":"554_CR18","first-page":"e57227","volume":"16","author":"A Kumar","year":"2024","unstructured":"Kumar A, Taneja A, Pal Singh Y, et al. Relationship between COVID-19 and Linezolid-Resistant Enterococci: a retrospective single-center study. Cureus. 2024;16(3):e57227.","journal-title":"Cureus."},{"issue":"1","key":"554_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-14-13","volume":"14","author":"BG Bell","year":"2014","unstructured":"Bell BG, Schellevis F, Stobberingh E, et al. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14(1):1\u201325.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"554_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/imj.12345","volume":"44","author":"C Hopkins","year":"2014","unstructured":"Hopkins C. Inpatient antibiotic consumption in a regional secondary hospital in N ew Z ealand. Intern Med J. 2014;44(2):185\u201390.","journal-title":"Intern Med J"},{"key":"554_CR21","unstructured":"Green T. Drug and therapeutics committees: a practical guide. In: Holloway K, \u200eeditor. World Health Organization. \u200e2003\u200e. Available from: https:\/\/iris.who.int\/handle\/10665\/68553."},{"issue":"1\u20132","key":"554_CR22","first-page":"16","volume":"5","author":"S Najafi","year":"2018","unstructured":"Najafi S, Keshavarz-Bahaghighat H, Kohneloo AJ, et al. A Survey of Linezolid Prescription before and after protocol implementation in a teaching hospital. J Pharm Care. 2018;5(1\u20132):16\u201320.","journal-title":"J Pharm Care."},{"key":"554_CR23","unstructured":"World Health Organization (WHO). Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance#:~:text=AMR%20is%20a%20natural%20process,in%20humans%2C%20animals%20and%20plants. Accessed\u00a021 Nov 2023"},{"issue":"10","key":"554_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/1469-0691.12751","volume":"20","author":"C Pulcini","year":"2014","unstructured":"Pulcini C, Botelho-Nevers E, Dyar OJ, et al. The impact of infectious disease specialists on antibiotic prescribing in hospitals. Clin Microbiol Infect. 2014;20(10):963\u201372.","journal-title":"Clin Microbiol Infect"},{"key":"554_CR25","doi-asserted-by":"publisher","unstructured":"Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev. 2010;6. https:\/\/doi.org\/10.1002\/14651858.CD007022.pub2.","DOI":"10.1002\/14651858.CD007022.pub2"},{"issue":"10","key":"554_CR26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.21037\/atm-20-3300","volume":"8","author":"J Wang","year":"2020","unstructured":"Wang J, Tang Y, Ma Y, et al. Efficacy and safety of antibiotic agents in children with COVID-19: a rapid review. Ann Transl Med. 2020;8(10):619.","journal-title":"Ann Transl Med."},{"issue":"2","key":"554_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3329\/bmj.v40i2.18495","volume":"40","author":"M Khan","year":"2011","unstructured":"Khan M, Ara N. Promoting rational prescribing among medical practitioners. Bangladesh Med J. 2011;40(2):6\u20137.","journal-title":"Bangladesh Med J"},{"issue":"4","key":"554_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/tcrm.2006.2.4.455","volume":"2","author":"R Manfredi","year":"2006","unstructured":"Manfredi R. Update on the appropriate use of linezolid in clinical practice. Ther Clin Risk Manag. 2006;2(4):455\u201364.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"554_CR29","first-page":"663","volume":"65","author":"PW Ament","year":"2002","unstructured":"Ament PW, Jamshed N, Horne JP. Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections. Am Fam Physician. 2002;65(4):663\u201371.","journal-title":"Am Fam Physician"},{"key":"554_CR30","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","volume":"59","author":"DC Vinh","year":"2009","unstructured":"Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect. 2009;59:S59\u201374.","journal-title":"J Infect"},{"issue":"10","key":"554_CR31","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00228-023-03542-z","volume":"79","author":"D Zhang","year":"2023","unstructured":"Zhang D, Xu Y, Wang X, et al. Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2023;79(10):1303\u201314.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"554_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/labmed\/lmaa067","volume":"52","author":"X Zong","year":"2021","unstructured":"Zong X, Gu Y, Yu H, et al. Thrombocytopenia is associated with COVID-19 severity and outcome: an updated meta-analysis of 5637 patients with multiple outcomes. Lab Med. 2021;52(1):10\u20135.","journal-title":"Lab Med"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-024-00554-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-024-00554-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-024-00554-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T13:03:38Z","timestamp":1745586218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-024-00554-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["554"],"URL":"https:\/\/doi.org\/10.1007\/s40199-024-00554-7","relation":{},"ISSN":["2008-2231"],"issn-type":[{"type":"electronic","value":"2008-2231"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"30 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of the Vice-Chancellor of Research at Baqiyatallah University of Medical Sciences approved this study (Ethical code: IR. BMSU. REC. 1399. 358). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}